此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

局部胰岛素对圆锥角膜患者角膜交联后角膜上皮愈合的影响

2026年11月2日 更新者:Vitor Borges Guimaraes、University of Campinas, Brazil

局部胰岛素对圆锥角膜患者角膜交联后角膜上皮愈合的影响:一项随机临床试验

The cornea plays a fundamental role in vision, being a complex tissue essential for ocular health. In ophthalmological practice, there are situations such as corneal crosslinking, where damage to the corneal epithelium occurs. Crosslinking is a surgical procedure aimed at strengthening collagen bonds in the corneal stroma to prevent the progression of keratoconus, through the application of topical riboflavin followed by ultraviolet (UV-A) radiation. To enhance the effectiveness of riboflavin and UV-A radiation, the corneal epithelium needs to be removed, which can cause postoperative pain and discomfort, as well as increase the risk of complications such as infections, scarring, corneal opacities, perforations, and recurrent epithelial erosions. Several growth factors play a role in epithelial healing, and the discovery of insulin in the tear film and the presence of insulin and Insulin-Like Growth Factor (IGF-1) receptors in the cornea has raised the hypothesis that insulin may modulate the cornea's wound healing response. Since then, topical insulin has been used for various ocular pathologies, including dry eye disease, persistent epithelial defects, and neurotrophic ulcers. Based on this knowledge, studies have been developed, and promising results regarding the use of insulin in corneal healing have been reported, providing a scientific foundation for the realization of this project.

The objective of this study was to evaluate the effect of insulin eye drops at a concentration of 50 IU/ml on epithelial healing in non-diabetic patients undergoing epithelial debridement for corneal crosslinking. To this end, a randomized, double-masked clinical trial was conducted with two groups, one being the control group, in which researchers compared the epithelial healing rate in mm²/h between the insulin group and the placebo group, as the primary outcome. Patients diagnosed with keratoconus and with an indication for the crosslinking procedure were invited to participate.

The study was designed to assess and quantify the impact of topical insulin on epithelial defect closure in patients undergoing crosslinking, compared to placebo.

研究概览

详细说明

Patients from the Keratoconus Clinic of the Hospital de Clínicas, State University of Campinas (UNICAMP), Brazil, with a diagnosis of keratoconus and an indication for corneal crosslinking were evaluated with visual acuity, refraction, slit-lamp biomicroscopy, Goldmann applanation tonometry, corneal specular microscopy (EM-3000, Tomey) for endothelial cell count, and corneal tomography (Pentacam HR, Oculus).

Eligible patients who signed the informed consent form (with the legal guardian also signing for participants younger than 18 years) underwent crosslinking. After the procedure, participants were allocated to two groups (insulin and placebo) by block randomization with blocks of four, stratified by sex. The random sequence was generated at random.org/lists and concealed in sealed opaque envelopes prepared by an independent assistant. Envelopes were opened sequentially at enrollment by investigators who did not take part in outcome assessment. One participant underwent crosslinking in both eyes, which were allocated to different groups; the eye was the unit of analysis.

Crosslinking was standardized for all participants and performed by third-year ophthalmology residents supervised by attending physicians. Central 8.0-mm epithelial debridement was performed with an optical zone marker of the same diameter: 30% alcohol was applied within the marker for 10 seconds and dried with an ophthalmic sponge, and the epithelium was removed with a corneal scarifier spatula. Riboflavin 0.1% (400 mOsm) in a hydroxypropyl methylcellulose vehicle was used, with UVA irradiation at 9 mW/cm² for 10 minutes (fluence 5.4 J/cm²) using the Eyelink Crosslink device (Eyetec, São Carlos, Brazil). At the end of the procedure, the size and shape of the debrided area were checked with the 8.0-mm marker, and participants whose debridement did not meet this standard were excluded.

The insulin group received NPH insulin 50 IU/mL eye drops (Eye Pharma, São Paulo, Brazil) four times daily, and the placebo group received 0.5% methylcellulose eye drops (Eye Pharma), the vehicle of the insulin formulation, four times daily, until complete epithelial healing. The bottles were identical and were labeled on the prescription as "compounded eye drops". Participants and outcome assessors were masked to group allocation. Both groups received moxifloxacin 5 mg/mL every 6 hours (Oftalmox; Geolab), prednisolone acetate 10 mg/mL every 6 hours (Ster; União Química), 0.15% sodium hyaluronate every 4 hours (Hyabak; Laboratoires Théa) and a silicone hydrogel bandage contact lens (Air Optix plus HydraGlyde; Alcon) until complete epithelial healing. Moxifloxacin and the study eye drops were then discontinued, and prednisolone was tapered weekly until one month after the procedure.

Crosslinking was always performed on Tuesdays, and assessments took place 18, 42 and 66 hours after the procedure (postoperative days 1 to 3). If epithelialization was incomplete at 66 hours, a further visit was scheduled on postoperative day 6 and every 48 hours thereafter until complete epithelialization. At each visit, the epithelial defect was photographed with the Keratograph 5M (OCULUS) and slit-lamp biomicroscopy was performed. The defect area was measured with ImageJ software by an investigator masked to allocation and reviewed independently by a second masked investigator. Complete epithelial healing was defined as the absence of an epithelial defect after fluorescein instillation on Keratograph 5M images, confirmed by two examiners on slit-lamp examination.

The primary outcome is the corneal epithelialization rate (mm²/h). Secondary outcomes are time to complete epithelialization and adverse events, in addition to endothelial cell density. Later follow-up visits took place at 30 and 60 days after crosslinking.

研究类型

介入性

注册 (实际的)

19

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • São Paulo
      • Campinas、São Paulo、巴西、13.083-887
        • State University of Campinas

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

14年 及以上 (孩子、成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Age 14 years or older
  • Diagnosis of keratoconus with an indication for corneal crosslinking

Exclusion Criteria:

  • Diabetes mellitus
  • Dry eye disease
  • Limbal stem cell deficiency
  • Glaucoma
  • Allergy to insulin or methylcellulose
  • Irregular epithelial debridement and/or debridement other than 8.0 mm during the crosslinking procedure

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
实验性的:Insulin

NPH insulin 50 IU/mL eye drops (Eye Pharma, São Paulo, SP, Brazil), one drop four times daily until complete corneal epithelialization, added to the standard postoperative regimen.

Insulin eye drops in the postoperative prescription for corneal crosslinking

其他名称:
  • 胰岛素
安慰剂比较:Placebo

0.5% methylcellulose eye drops (Eye Pharma, São Paulo, SP, Brazil), the vehicle of the insulin formulation, one drop four times daily until complete corneal epithelialization, added to the standard postoperative regimen.

Placebo eye drops of 0.5% Methylcellulose in the postoperative prescription for corneal crosslinking

其他名称:
  • 安慰剂

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Corneal Epithelial Healing Rate
大体时间:From crosslinking until complete epithelialization, assessed at 18, 42 and 66 hours, on day 6 and every 48 hours thereafter.

Rate of corneal re-epithelialization (mm²/h), calculated as the epithelial defect area at the first postoperative assessment (18 hours) divided by the time elapsed until complete epithelialization. Defect area measured on Keratograph 5M (OCULUS) images with ImageJ software by masked investigators.

From crosslinking until complete epithelialization, assessed at 18, 42 and 66 hours, on day 6 and every 48 hours thereafter.

次要结果测量

结果测量
措施说明
大体时间
Endothelial cell count
大体时间:60 days

Endothelial cell count loss in each group, if any

60 days
Incidence of corneal haze
大体时间:60 days.

Incidence of corneal haze in each group.

60 days.
Time to complete epithelialization
大体时间:From crosslinking until complete epithelialization.

Time (hours) from crosslinking to the first assessment at which complete epithelial closure was documented (absence of an epithelial defect after fluorescein instillation on Keratograph 5M images, confirmed on slit-lamp examination). Closure could only be ascertained at scheduled visits.

From crosslinking until complete epithelialization.
Adverse events
大体时间:From crosslinking until the end of follow-up.

Number of eyes with ocular adverse events (e.g., infectious keratitis, sterile infiltrates, persistent epithelial defect, allergic reaction to study eye drops) recorded at each study visit.

From crosslinking until the end of follow-up.

其他结果措施

结果测量
措施说明
大体时间
Epithelial Defect Area
大体时间:18, 42 and 66 hours after crosslinking.

Area of the corneal epithelial defect (mm²) measured on Keratograph 5M images with ImageJ software.

18, 42 and 66 hours after crosslinking.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 学习椅:Monica Alves, PhD、State University of Campinas (Unicamp)

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年8月1日

初级完成 (实际的)

2025年12月25日

研究完成 (实际的)

2026年3月20日

研究注册日期

首次提交

2024年9月15日

首先提交符合 QC 标准的

2024年9月15日

首次发布 (实际的)

2024年9月19日

研究记录更新

最后更新发布 (实际的)

2026年11月5日

上次提交的符合 QC 标准的更新

2026年11月2日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

The de-identified dataset analyzed during the current study is available from the corresponding author on reasonable request.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅